Bryan Fischer
Don't let them lie to you: HCQ still drug of choice
FacebookTwitterGoogle+
By Bryan Fischer
June 3, 2020

While the Coronavirus curve has been flattened – along with religious liberty and the American economy – it is still a threat to some. And Hydroxychloroquine (HCQ) is still the drug of choice to prevent it and cure it.

Now the Deep State in the medical community do not want you or the world to know that. The reason is as old as commerce itself: follow the money. There is a $6 billion to $19 billion payday for the Big Pharma company which comes up with a vaccine. But since HCQ is a generic, BIg Pharma ain’t gonna make nothing off it if it gets recognized as the standard of care.

So the Big Pharma Deep State literally has billions of reasons to sabotage HCQ trials and convince the world that it’s a dangerous, even lethal, drug. If they can get a close adviser to the president to publicly pooh-pooh it on national TV, all the better. Once the word gets out that it stops COVID-19 in its tracks and functions just like a vaccine, it’s game over for Big Pharma. You can get a bottle of HCQ at Fred Meyer for $14.95.

Opponents of affordable health care of the COVID variety have managed to convince the world that HCQ poses a serious risk to heart health, despite no evidence of that at all. HCQ has been used since the 1940s to treat malaria, lupus, and rheumatoid arthritis without any serious side effects. I received an email from a listener who has been taking HCQ for RA for 42 years with no side effects at all.

If used early in treatment as soon as symptoms appear, it is highly effective as a treatment for the Communist Chinese virus. This is why the FDA, part of the Deep State, has diabolically restricted its use to people who are so sick they have to be hospitalized, because they don’t want people using it early in the game. By restricting it to an already medically compromised population, they increase the numbers of patients on HCQ with bad outcomes, which in turn makes the drug easier to demonize.

Problematically for Big Pharma saboteurs, on May 27 Dr. Harvey Risch of Yale published an article in the prestigious American Journal of Epidemiology with the title, “Early Outpatient Treatment of Symptomatic, High-Risk Covid-19 Patients that Should be Ramped-Up Immediately as Key to the Pandemic Crisis.” (Emphasis mine.) In other words, getting treatment started right away is crucial to solving the COVID-19 problem. But that’s not what Big Pharma wants.

Dr. Risch, after looking at the data from five clinical trials, discovered no cardiac problems on the one hand and “significant major out-patient efficacy” on the other. That’s with HCQ used in combination with azithromycin (HCQ+AZT). His conclusion is that if we are serious about helping folks with COVID-19, these medications need to be widely available and promoted immediately for physicians.”

Speaking of heart problems, the FDA’s drug evaluation database lists exactly 62 cardiac deaths out of 50 million prescriptions. A large Oxford-based study which involved more than 300,000 patients with rheumatoid arthritis resulted in an estimate of just 47 cardiac arrhythmias per 100,000 patients. And most of those were not fatal. You have ten times the risk of dying in an automobile accident.

So how does the media neutralize this bombshell information? First of all, it ignores the Yale Report altogether in favor of focusing on flawed studies of patients who aren’t given HCQ until they are critically ill with severe organ damage. See, it doesn’t do any good, and it might even kill you!

A much-touted study from Brazil, published in the Journal of the American Medical Association in April, is likewise seriously flawed. It too started with patients who were already debilitated and critically ill and had multiple co-morbidities to boot. Then, if you can believe it, researchers gave them double the known lethal dose of chloroquine, and then acted surprised when patients began dropping like flies.

A recent report in the medical journal Lancet also reviewed only the cases of severely ill and already hospitalized patients. There are numerous questions about the validity and accuracy of the data.

Dr. Elizabeth Lee Vliet, past Director of the Association of American Physicians and Surgeons, points out that Tylenol, Aleve, and Advil have health risks of their own that most people don’t think twice about. Tylenol is the number one cause of acute liver failure in the U.S. while Aleve and Advil together account for 21% of all adverse drug events in the U.S. I think we can handle the zero side effects of HCQ.

She also points out that countries that use HCQ prophylactically, instead of waiting until patients are almost dead, “have dramatically lower COVID-19 death rates than the U.S.” The death rate in the U.S. is 20 times higher than that of India and 265 times the FDA’s hysterically exaggerated estimate of HCQ-related heart problems.

The President has the legal authority under the Defense Production Act to bypass the FDA and make HCQ readily available to Americans while this pandemic runs its course. It’s long past time for Americans to have the option of HCQ as they make decisions regarding their own health.

It saves lives, it's inexpensive, and it’s safer than Tylenol, Advil, and Aleve. What’s not to like?

The author may be contacted at bfischer@afa.net

Follow me on Facebook at “Focal Point” and on Twitter @bryanjfischer

Host of “Focal Point” on American Family Radio, 1:05 pm CT, M-F www.afr.net

© Bryan Fischer

 

The views expressed by RenewAmerica columnists are their own and do not necessarily reflect the position of RenewAmerica or its affiliates.
(See RenewAmerica's publishing standards.)